Schering-Plough drug effective for ovarian cancer
The overall tumor response rate of 63% shown by Caelyx plus platinum combination was associated with a complete response rate of 38%, a median survival of 32 months
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.